Overview

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Status:
Completed
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.
Phase:
Phase 1
Details
Lead Sponsor:
Ascentage Pharma Group Inc.
Collaborator:
HealthQuest Pharma Inc.